Early initiation of SGLT2 inhibitors is important, irrespective of ejection fraction: SOLOIST‐WHF in perspective

The ultimate primary endpoint of SOLOST‐WHF—which in order to preserve statistical power was changed because of the premature closure of the study due to loss of funding from the sponsor during the onset of the COVID‐19 pandemic—was the composite of total HHF, urgent heart failure visits, or cardiovascular deaths The HR for the primary outcome was apparently similarly reduced in all groups (0 69, 0 74, and 0 66, respectively) Because the subgroup of patients with ejection fraction above 50% was modest in size, further data of SGLT2 inhibitors in heart failure with preserved ejection fraction (HFpEF) are eagerly anticipated 2 Figure DAPA‐HF, Study to Evaluate the Effect of Dapagliflozin on the Incidence of Worsening Heart Failure or Cardiovascular Death in Patients With Chronic Heart Failure;EF, ejection fraction;EMPEROR‐Reduced, EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Reduced Ejection Fraction;GDMT, guideline‐directed medical therapy;HFrEF, heart failure with a reduced ejection fraction;MRA, mineralocorticoid receptor antagonists;RASi, renin‐angiotensin system inhibitors;WHF, worsening heart failure The EMPEROR‐Preserved (EMPagliflozin outcomE tRial in Patients With chrOnic heaRt Failure With Preserved Ejection Fraction) 34 and DELIVER (Dapagliflozin Evaluation to Improve the LIVEs of Patients With PReserved Ejection Fraction Heart Failure;ClinicalTrials gov Identifier: NCT03619213) trials that are ongoing will provide valuable information in those with HFpEF in the ambulatory setting